Composition for treating epstein-barr virus infection, comprising epstein-barr virus micro rna inhibitor

A method for screening a therapeutic agent for treating Epstein-Barr virus infection, the method comprising:

• 1) treating Epstein-Barr virus-positive cells with miR-BART20-5p represented by SEQ ID NO:
• 4 or a miR-BART20-5p analogue represented by SEQ ID NO:
• 5 or SEQ ID NO:6;
• 2) treating the cells with a candidate therapeutic agent;
• and
• 3) determining whether the induction of lytic cycle is induced in the cells.

A method for screening a therapeutic agent for treating Epstein-Barr virus infection, the method comprising the steps of:

• 1) treating cells that express BRLF1 3′UTR or BZLF1 3′UTR of Epstein-Barr virus with miR-BART20-5p represented by SEQ ID NO:
• 4 or a miR-BART20-5p analogue represented by SEQ ID NO:
• 5 or SEQ ID NO:
• 6;
• 2) treating the cells with a candidate therapeutic agent;
• and
• 3) determining whether BRLF1 3′UTR or BZLF1 3′UTR is expressed in the cells.